What's Hot

GLP-1 Medications and Alcohol: What the Research Does and Does Not Show

bowl on a rack picture

GLP-1 medications are among the most discussed drugs in medicine, first for diabetes and weight loss and now for a question their approved labels do not cover: can they help people drink less? Interest in the link between GLP-1 medications and alcohol has grown faster than the research.

GLP-1 stands for glucagon-like peptide-1, a hormone released in response to food, and an agonist is a drug that activates a receptor, so a GLP-1 receptor agonist mimics that signal. Alcohol use disorder, or AUD, is the diagnosis for a drinking pattern that causes harm or distress. No GLP-1 medication is FDA-approved for AUD.

ADVERTISEMENT
ADVERTISEMENT

Why researchers are looking at GLP-1s for drinking

The GLP-1 system does more than manage blood sugar. Drugs that activate its receptor change glucose control, appetite and digestion, which is why they are prescribed for diabetes and weight management. The same receptor appears in brain circuits, and researchers are studying how GLP-1 signals affect the systems that drive reward seeking.

Animal work offers a possible mechanism. A 2025 rodent study examined the lateral septum, a brain region involved in reward, and found that GLP-1 signaling there changed alcohol intake. That is a lead, not a result in people.

The human clue came from patients. People taking GLP-1s for diabetes or weight loss began reporting that they drank less, and the reports were consistent enough to justify trials. If the effect is real, a GLP-1 medication would add an option to a short list of approved medications.

What the trials have actually measured

A randomized trial assigns participants to a drug or a placebo by chance, the design that can show whether a medication caused a change. The GLP-1 alcohol trials are small, and each measured something different.

A 2025 trial led by Christian Hendershot at the University of Southern California tested weekly semaglutide in 48 adults with AUD who were not seeking treatment. Over about nine weeks it reduced alcohol consumed in a laboratory task, drinks per drinking day and craving. It did not significantly change drinking days or drinks per calendar day.

A larger 2026 trial in The Lancet tested semaglutide in 108 treatment-seeking adults with AUD and obesity, alongside standard cognitive behavioral therapy. Over 26 weeks, heavy-drinking days fell 41.1 percentage points with semaglutide and 26.4 with placebo, a 13.7-point difference. Gastrointestinal side effects were more common with the drug.

An eight-week trial of oral semaglutide reported in the American Journal of Psychiatry in 2026 found no significant reduction in laboratory-assessed craving or drinks per day among 50 adults, but fewer heavy-drinking days. Three trials, three sets of endpoints, one mixed picture.

What the large medical-record studies found

Medical records answer a different question. An observational study follows people in routine care and compares those who received different treatments. It does not assign treatment by chance, so it shows associations but not cause.

A 2024 study in Nature Communications linked semaglutide with fewer first-time or repeat AUD diagnoses among people with obesity or diabetes. A 2025 study in JAMA Psychiatry linked semaglutide and liraglutide with a lower risk of hospitalization for AUD.

A large analysis, in BMJ Open in 2026, followed 40,703 adults with AUD and diabetes or obesity. Against sulfonylureas, newer GLP-1 use was associated with a hazard ratio of 0.74 for alcohol-related emergency care or hospitalization. The ratios were 0.78 against other diabetes medications and 0.68 against other obesity medications. A hazard ratio below 1 means fewer events in the GLP-1 group.

A November 2026 records study found that among adults with type 2 diabetes, semaglutide and tirzepatide were each associated with fewer recorded AUD-related hospital or emergency visits than SGLT2 inhibitors over about a year. There was no clear difference between the two.

The outcome in the records studies is a diagnosis or a hospital visit. A diagnosis of alcohol use disorder, a hospital visit, a heavy-drinking day and a craving score are different outcomes, and a lower rate of one does not establish an identical reduction in the others.

Where the evidence is still thin

The picture that emerges from the evidence on GLP-1s and alcohol is uneven. Some medical-record studies found no clear reduction in alcohol-related admissions, and in one a difference in weekly drinking faded after accounting for weight change.

The trials leave gaps of their own. They were small, they ran for weeks rather than years, and they enrolled people with AUD, obesity or both. None compared a GLP-1 directly with an approved AUD medication, and one open question is whether GLP-1s work better alongside mental and behavioral health care.

Patient surveys sit at the weakest level of evidence. A national survey reported in JAMA Psychiatry in October 2026 found that 44.2 percent of 242 GLP-1 users reported drinking less in the first three months, 52.6 percent no change and 3.3 percent drinking more. It relied on memory, so it cannot show that the medication caused the change.

Open questions remain: who benefits most, whether changes last after the medication stops, and which doses and forms work best.

What a patient should ask a clinician

Anyone considering a GLP-1 for drinking should start with a clinician who can review the whole picture, including other health conditions and other medications.

A first question is whether the drinking pattern falls in a range where medication is considered at all. A second is which outcomes will be tracked. Heavy-drinking days, craving, sleep, blood pressure and liver tests measure different things.

It is worth asking which medications are approved for AUD and how they compare with a GLP-1. The National Institute on Alcohol Abuse and Alcoholism lists naltrexone, acamprosate and disulfiram as evidence-based options.

If a GLP-1 is suggested, the next questions are whether it is prescribed for an approved use or outside one, which side effects are common, what happens when it stops and whether counseling belongs in the plan.

The same institute warns that alcohol withdrawal can be life-threatening for people who have been drinking heavily for a long time, so a sudden stop should be planned with medical advice.

The honest summary

The research does show something. Small trials found that semaglutide reduced heavy-drinking days and some measures of drinking and craving; medical-record studies found fewer AUD diagnoses and hospital visits.

The research does not show that any GLP-1 treats AUD. It does not show that these drugs outperform naltrexone, acamprosate or disulfiram, that benefits persist after treatment stops, or that results from people with obesity and AUD apply to everyone. Two phase 3 trials of brenipatide, an investigational drug, should answer some of these questions.

Until then, GLP-1s are promising for AUD and unproven as a treatment for it. Regulators have not approved any GLP-1 for AUD.

This is educational information, not medical advice; a licensed clinician decides what is appropriate.

Share this article
Leave A Reply

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADVERTISEMENT